Congratulations Ivaska Lab! What a great honor for us to contribute to this elegant piece of science! The cell microarray technologies still got it😃 Interested to develop your custom microarray platform? Contact us for more info! pnas.org/doi/10.1073/pn…@IvaskaLab@PNASNews
Target discovery using RNAi screening is still a valid approach. This time a novel DDR target FBXL12 for cancer therapy. Congratulations Sangfelt Lab! sciencedirect.com/science/articl…
Last Call! Calling all early career researchers interested on nanomedicine and looking for a PhD position. Application period to @MelomanesMSCA training network is closing! #PhDmelomanes.eu/recruitment/
CancerBio Summer School and Cancer IO present:
Special #Sebinar on "Hallmarks of Cancer: New Dimensions" by Professor Douglas Hanahan, the Swiss Institute for Experimental Cancer Research @EPFL_en
Welcome to join the Zoom event on 25 May at 13-14 EEST helsinki.zoom.us/j/64902684556?…✨
Do you want to join a team of scientists working towards precision toxicology? The University of Birmingham is looking for a Data Analyst in Bioinformatics and Biostatistics - deadline: 26th of May
bham.taleo.net/careersection/…
During these dark times one needs to find happiness from the small things. Well, today we celebrate our 8th anniversary! What a ride it’s been. Great science, great projects and most importantly great people and customers. Thank you for allowing us to work with you🥂🎉
Are you interested in the regulation of mesenchymal tumor phenotype in human cancers. Check out our latest work fresh off the press at Molecular Cell. doi.org/10.1016/j.molc…
The first version of the Cancer IO Ecosystem map is now online! See the map and check the key players in the Finnish IO Ecosystem.
At this stage, the map includes all Cancer IO partners. Would you like to be involved - contact us! cancerio.org/en/ecosystem/@BusinessFinland
Even some of the most rare cancers can be caused by well known cancer susceptibility genes. Read our study on DNA repair targeting in an extreme rare cutaneous apocrine carcinoma associated with a Finnish founder mutation on PALB2. doi.org/10.18632/oncot…#rarecancer
Interested in tailor made peptidyl diphenyl phosphonate warheads for analysis of proteolytic networks? Check out our latest collaborative study in Nature Chemical Biology: nature.com/articles/s4158…
Small but mighty! According to the latest H2020 country statistics, Misvik is ranked second among all Finnish life science, pharma and biotech companies in the number of participation to EC funded research and innovation projects! #IndustrialLeadership#H2020#misvikbiology
Last week marked the kick-off of our 6th H2020 EU-funded project HARMLESS. The purpose of the project is to provide tools, guidance and decision support to ensure that the next generation nanomaterials will be harmless! #HARMLESS#IndustrialLeadership#SafebyDesign